GUIDE TO GOOD MANUFACTURING PRACTICE …
Introduction PE 009-8 (Part II) - 1 - 15 January 2009 1. INTRODUCTION 1.1 Objective This document (Guide) is intended to provide guidance regarding good manufacturing
Download GUIDE TO GOOD MANUFACTURING PRACTICE …
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
Presents a 3-Day Training Course on: Aseptic …
www.candvs.comCompliance & Validation Services Presents a 3-Day Training Course on: Aseptic Manufacturing of Pharmaceutical Products 17, 18 & 19 April 2018 Radisson Blu Hotel, Amsterdam
Hygienic Design of Food Manufacturing Premises …
www.ifst.orgHygienic Design of Food Manufacturing Premises Dr. John Holah Technical Director IFTS Hygienic Design Conference 25 th February 2016
PLANNING OF PHARMACEUTICAL FACTORIES - …
www.ispeth.orgPLANNING OF PHARMACEUTICAL FACTORIES CONCEPT AND IMPLEMENTATION WORLD CLASS PHARMA FACILITY PRESENT SCENARIO : The globalization and open market policies have proved to be a boon for
GMP Design of Pharmaceutical Facilities - ISPE Th
www.ispeth.orgGMP Design of Pharmaceutical Facilities Process design Layouts and Flow Diagrams OSD Facilities Biopharma and Aseptic facilities
CELL CULTURE BASICS - Vanderbilt University | …
www.vanderbilt.eduIntroduction Cell Culture Basics | 1 Purpose of the Handbook Cell Culture Basics Companion Handbook is a supplement to the Cell Culture Basics
guide to master formulae final - WHO
www.who.intDraft: Guide to Master Formulae. 3 1) Introduction In the 1997 WHO guidance document: “WHO/VSQ/97.01: ( A WHO guide to good manufacturing practice (GMP) requirements.
RADIOPHARMACEUTICALS - WHO
www.who.intDocument QAS/08.262/FINAL page 3 content may be such that an unacceptable radiation dose would be delivered to the patient. The shelf-life of a multidose radiopharmaceutical preparation, after aseptic withdrawal of